PEI Staff

Accella Performance Materials, a maker of polyurethanes and recycled rubber products, acquired Quadrant Urethane Technologies' spray foam division, Quadrant Spray Foam. Based in McKinney, Texas Quadrant Spray Foam makes spray foams for insulation. Accella has been backed by Arsenal Capital Partners since 2012.

PledgeMusic, a direct-to-fan e-commerce platform, agreed to acquire NoiseTrade and Set.fm. Financial terms of the deal were not disclosed. Set.fm raised $1.2 million in seed funding from Golden Venture Partners in 2013.

 Vicente Capital Partners MedBridge Healthcare, a provider of sleep diagnostic testing and respiratory therapy services, merged with Sleep Services of America, a wholly-owned subsidiary of the Johns Hopkins Health System. Vicente Capital Partners acquired MedBridge in 2008.

Welsh, Carson, Anderson & Stowe agreed to acquire QuickBase from Intuit Inc. Based in Cambridge, Massachusetts, QuickBase offers a development platform with a low-code interface, enabling users to create custom applications without learning code. Financial terms of the deal were not disclosed.  

Charlesbank Capital Partners hired Neil Kalvelage as operating partner. Kalvelage joins Charlesbank from Bain Capital, where he worked for 10 years as operating partner, most recently building a team in Melbourne, Australia. He has also held executive positions at The Hershey Co and PepsiCo.

Medical technology company Becton, Dickinson and Co agreed to sell 50.1 percent of its Respiratory Solutions business to Apax Partners and form a joint venture that will operate as a new, independent company. The transaction values the entire business today at nearly $500 million. The new company will have estimated annual revenue of approximately $900 million.

Linsalata Capital Partners, a Cleveland-based private equity firm, promoted Jeffrey S. Wahl to managing director and operating partner. Wahl joined Linsalata in 2014 from private equity-backed EdisonLearning, where he was president and chief executive. The firm also promoted Murad A. Beg to managing director and James V. Guddy to principal.

Tizona Therapeutics Inc, a company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases, raised $43 million in Series B funding. Abingworth and Canaan Partners led the round with participation from Lightstone Ventures and existing Series A investors, including MPM Capital, Amgen Ventures, Astellas Venture Management and InterWest Partners.